Market Newsdesk

March 9, 2022

• As an initial remote monitoring diagnostic approach, Philips BioTel Heart MCOT detected 4.6 times more patients
  with atrial fibrillation compared to implantable loop recorder alone
• Almost eight times lower costs were achieved with improved detection rates and reduction of secondary stroke risk
• Remote cardiac monitoring via the MCOT patch reduced the total cost per patient with detected atrial fibrillation by USD 198,909 compared to monitoring with ILR only
• Findings validate 30-day remote cardiac monitoring program as cost-effective standard of care for cryptogenic stroke patients compared to ILR alone

Amsterdam, the Netherlands –

Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced new research evaluating mobile cardiac outpatient telemetry (MCOT) as a first-line diagnostic ambulatory monitoring solution with post-cryptogenic stroke patients. The study determined that a 30-day continuous monitoring program using the Philips BioTel Heart MCOT patch, followed by an implantable loop recorder (ILR), improved atrial fibrillation (AF) detection rates and helped to reduce secondary stroke risk due to new anticoagulant use in subjects with the MCOT patch detected AF. The study also demonstrated that use of initial MCOT monitoring achieved almost eight times lower costs, reducing the total cost per patient with detected atrial fibrillation (AF) by USD 198,909 [1], compared to monitoring with ILR only.  These results strengthen recommendations for prolonged ECG monitoring for this patient population.

Globally, about one in four people over the age of 25 will suffer a stroke in their lifetime [2]. Nearly a third of Ischemic strokes – the result of blood clots that block the flow of blood to the brain – are classified as cryptogenic, meaning the cause is unknown [3]. These situations require post-stroke diagnostic work to determine the cause and prevent a second stroke from occurring. AF is a common cause and can increase the risk of stroke by more than five times [4], but it often goes undetected since it can be asymptomatic and may occur infrequently.

The study evaluated a stroke population of 1,000 for one year to assess the differences in costs and outcomes of two monitoring options that are available to clinicians today to help improve patient care and improve efficiencies within the healthcare system. Findings revealed using an MCOT patch followed by ILR in half of patients initially undiagnosed with AF leads to an overall cost-of-care savings of more than USD 4 million. Philips BioTel Heart MCOT detected 4.6 times more patients with AF than ILR alone. And for those with detected AF, the cost per patient was significantly lower when using the MCOT patch followed by ILR (USD 29,598) than those being monitored with ILR alone (USD 228,507).

“The diagnostic tools clinicians use to monitor this group of patients play an important role in finding the cause of the stroke and developing a personalized treatment plan,” said Andy Broadway, General Manager of Ambulatory Monitoring and Diagnostics at Philips. “This new research confirms that using Philips BioTel Heart MCOT as the first line of evaluation is more cost-effective and can provide the level of diagnostic confidence needed to help detect and diagnose atrial fibrillation, and potentially prevent a second stroke.”

Patients were monitored for 30 days and were included in one of two monitoring arms in the model: The MCOT patch arm where Philips BioTel Heart MCOT was used followed by ILR in undetected AF patients for 30 days, or the ILR arm where ILR served as the only monitoring tool.

Philips solutions across care pathways

Philips offers a complete portfolio of clinically validated ambulatory cardiac diagnostic and monitoring services as well as stroke care solutions that provide industry-leading data analysis and management to help make care delivery more comprehensive, accurate and efficient.
These solutions aim to connect information, technologies and people across both the stroke and cardiac care pathways, enabling care teams to work quickly and act decisively to provide the best patient treatment. The new research results illustrate the company’s strong commitment to further innovation in this field.

For more information on Philips’ full portfolio of cardiology solutions being showcased during the HIMSS22 Global Health Conference & Exhibition, please visit www.philips.com/himss and follow @PhilipsLiveFrom for #HIMSS22 updates throughout the event.

[1] Difference in cost per patient with detected AF monitored with ILR ($228,507) minus cost per patient with detected AF patients using the MCOT patch ($29,598). Medic G, Kotsopoulos N, Connolly MP, Lavelle J, Norlock V, Wadhwa M, Mohr BA, Derkac WM. Mobile Cardiac Outpatient Telemetry Patch vs Implantable Loop Recorder in Cryptogenic Stroke Patients in the US – Cost-Minimization Model. Med Devices (Auckl). 2021 Dec 18;14:445-458. doi: 10.2147/MDER.S337142. PMID: 34955658; PMCID: PMC8694406. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694406/

[2] Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, Fisher M, Pandian J, Lindsay P. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. Int J Stroke. 2022 Jan;17(1):18-29. doi: 10.1177/17474930211065917. PMID: 34986727. https://pubmed.ncbi.nlm.nih.gov/34986727

[3] Finsterer J. Management of cryptogenic stroke. Acta Neurol Belg. 2010 Jun;110(2):135-47. PMID: 20873443. https://pubmed.ncbi.nlm.nih.gov/20873443

[4] Oladiran O, Nwosu I. Stroke risk stratification in atrial fibrillation: a review of common risk factors. J Community Hosp Intern Med Perspect. 2019;9(2):113-120. Published 2019 Apr 12. doi:10.1080/20009666.2019.1593781 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484493/

For further information, please contact:

Meredith Amoroso
Philips Global Press Office
Tel: +1 724-584-8991
E-mail: [email protected]

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• A care provider applies and explains Philips MCOT patch

SHENZHEN, China, March 09, 2022 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading mobile developer service provider in China, today announced the successful completion of its previously announced acquisition of a majority equity interest in Wuhan SendCloud Technology Co., Ltd. (“SendCloud”).

About Aurora Mobile Limited

Founded in 2011, Aurora Mobile is a leading mobile developer service provider in China. Aurora Mobile is committed to providing efficient and stable push notification, one-click verification, and app traffic monetization services to help developers improve operational efficiency, grow and monetize. Meanwhile, Aurora Mobile’s vertical applications have expanded to market intelligence, and financial risk management, empowering various industries to improve productivity and optimize decision-making.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as Aurora Mobile’s strategic and operational plans, contain forward-looking statements. Aurora Mobile may also make written or oral forward-looking statements in its reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Aurora Mobile’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Aurora Mobile’s strategies; Aurora Mobile’s future business development, financial condition and results of operations; Aurora Mobile’s ability to attract and retain customers; its ability to develop and effectively market data solutions, and penetrate the existing market for developer services; its ability to transition to the new advertising-driven SAAS business model; its ability maintain or enhance its brand; the competition with current or future competitors; its ability to continue to gain access to mobile data in the future; the laws and regulations relating to data privacy and protection; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and Aurora Mobile undertakes no duty to update such information, except as required under applicable law.

For general inquiry, please contact:

Aurora Mobile Limited

E-mail: [email protected]

Christensen

In China

Mr. Eric Yuan
Phone: +86-10-5900-1548
E-mail: [email protected]

In US

Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: [email protected]

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

3-8-22

LONDON, March 09, 2022 (GLOBE NEWSWIRE) — Berkshire Grey Inc. (Nasdaq: BGRY), a leader in AI-enabled robotic solutions that automate supply chain processes, and Tessiant, a leading change and transformation consultancy, today announced their partnership to help transform supply chain operations through intelligent robotic automation of eCommerce fulfillment, store replenishment, package handling and logistics. Together, the two companies will give UK retailers access to the most advanced AI-enabled robotic solutions designed to meet consumer expectations for on-demand order fulfillment.

“Berkshire Grey’s portfolio of Intelligent Enterprise Robotic (IER) solutions is what many UK retailers are searching for during this confluence of challenges including the eCommerce boom, labour shortages and rising consumer expectations,” said Anna Barsby, Managing Partner at Tessiant. “We are excited to partner with Berkshire Grey to help our clients overcome these issues and improve supply chain operations with AI-enabled robotics.”

Labour shortages are pervasive throughout Europe, with the number of job vacancies in the UK alone rising to a new record of 1.3 million in January 2022. This is further compounded by ever-increasing consumer demands for instantaneous order fulfillment and lingering COVID issues. Supply chain leaders are under more pressure than ever to find new solutions that increase efficiency and order processing throughput in eCommerce fulfillment, store replenishment and package handling. With the launch of this partnership, UK companies will now have access to Berkshire Grey’s extensive robotic solutions and services including design, installation, testing and commissioning, and continued support leveraging cloud-based AI solutions for predictive maintenance, management of system operations, analytics and integration.

“We look forward to working side-by-side with Tessiant to advise the top retailers and eCommerce providers in the UK on how to leverage AI-enabled robotic solutions that can help them transform their supply chain,” said Neil Berry, Senior Vice President and General Manager for EMEA at Berkshire Grey. “Berkshire Grey and Tessiant both believe robotics are essential to help retailers stay competitive amid the growing market challenges, and we’re happy to partner with them to bring unique solutions to their network of clients.”

With this partnership, Tessiant will join Berkshire Grey’s Partner Alliance (BGPA) program as a Consulting Partner. The BGPA program includes a select group of strategic partners that provide customers across the retail, eCommerce, 3PL, grocery, and package handling industries with scalable robotic solutions developed to improve fulfillment throughput while driving down operational costs. The BGPA program consists of market-leading consultants, integrators, technology providers and material handling leaders dedicated to providing value-added, AI-enabled robotic solutions to customers.

To learn more about Berkshire Grey, please visit BerkshireGrey.com and follow Berkshire Grey on Facebook, LinkedIn, Twitter and YouTube.

About Tessiant

Tessiant is a Management Consultancy focused on shaping and delivering change. Tessiant helps clients deliver their critical projects, provides strategic advice through its network of C-suite practitioners, and embeds change through a focus on people and culture.

Tessiant consultants include specialists from a range of backgrounds such as Technology, Supply Chain, Operations, Digital, Data, Procurement and People, providing clients with the capability and capacity they need. Tessiant recognise that ‘not one size fits all’, so prides itself on being adaptable, pragmatic, and tailoring the team and approach to the situation.

Tessiant clients include retail, CPG, manufacturing, SIS, non-profit and private equity organisations. For more information go to www.tessiant.com.

About Berkshire Grey

Berkshire Grey (Nasdaq: BGRY) helps customers radically change the essential way they do business by delivering game-changing technology that combines AI and robotics to automate fulfillment, supply chain, and logistics operations. Berkshire Grey solutions are a fundamental engine of change that transform pick, pack, move, store, organize, and sort operations to deliver competitive advantage for enterprises serving today’s connected consumers. Berkshire Grey customers include Global 100 retailers and logistics service providers. More information is available at www.berkshiregrey.com.

Berkshire Grey and the Berkshire Grey logo are registered trademarks of Berkshire Grey. Other trademarks referenced are the property of their respective owners.

Contacts:

Method Communications for Berkshire Grey
[email protected]

Sara Buda
VP Investor Relations, Berkshire Grey
[email protected]

VANCOUVER, British Columbia, March 09, 2022 (GLOBE NEWSWIRE) — Pretium Resources Inc. (TSX/NYSE: PVG) (“Pretivm” or the “Company”) today announced that the previously announced acquisition of the Company by Newcrest Mining Limited (ASX/TSX/PNGX: NCM) (“Newcrest”) by way of a plan of arrangement (the “Transaction”) has been successfully completed.

Information for Former Pretivm Shareholders

Pretivm has applied to cease being a reporting issuer and the Pretivm shares are expected t0 be delisted from the Toronto Stock Exchange (“TSX”) on or about the closing of trading on March 11, 2022. The Pretivm shares are suspended from trading as of March 9, 2022 and will be delisted from the New York Stock Exchange (“NYSE”) and deregistered under the U.S. Securities Exchange Act of 1934, as amended (the “U.S. Exchange Act”), in accordance with applicable law.

Under the terms of the Transaction, Pretivm shareholders were able to elect, prior to 5:00 p.m. (Vancouver time) on January 18, 2022, to receive the consideration for their Pretivm shares in cash (the “All Cash Consideration”) or Newcrest shares (the “All Share Consideration”), subject to proration to ensure aggregate cash and Newcrest share consideration each represent 50% of total transaction consideration. Pretivm shareholders who did not make an election will receive the default consideration of C$9.25 per Pretivm share in cash and 0.4042 Newcrest shares per Pretivm share (the “Default Consideration” and together with the “All Cash Consideration” and the “All Share Consideration”, the “Consideration”).

Valid elections representing approximately 50.51% of the outstanding Pretivm shares were received by the election deadline. As a result, all holders of Pretivm shares who made an election will be subject to the following proration:

• Pretivm shareholders who elected to receive the All Cash Consideration will receive approximately C$
  10.81
  in cash and
  0.3357
  Newcrest shares per Pretivm share; and
• Pretivm shareholders who elected to receive the All Share Consideration will receive 0.8084 Newcrest shares per Pretivm share.

Information regarding the procedure for exchange of shares for Consideration is provided in the Company’s management information circular dated December 16, 2021 related to the Meeting (the “Circular”). The Circular and accompanying letter of transmittal and election form (the “Letter of Transmittal”) are available under the Company’s profile on SEDAR at www.sedar.com, on EDGAR at www.sec.gov and on the Company’s website at www.pretivm.com/investors/Newcrest-Transaction. Registered Pretivm shareholders who have not already done so must complete and sign the Letter of Transmittal and return it, together with the certificate(s)/DRS advice(s) representing their shares and any other required documents and instruments, in accordance with the procedures set out in the Letter of Transmittal. Non-registered Pretivm shareholders who hold their shares through a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary or depository (each, an “Intermediary”) who have not already submitted a Letter of Transmittal should contact their Intermediary for instructions and assistance in receiving the Consideration.

About Pretivm

Pretivm is an intermediate gold producer with the 100%-owned, high-grade gold underground Brucejack Mine located in northwestern BC. We strive for operating excellence and our first priority is the health and safety of our employees, contractors and neighbouring communities. We are committed to the principles of sustainable development and conducting our activities in an environmentally and socially responsible manner.

Pretivm Contact

Pretium Resources Inc.
Troy Shultz, Director, Investor Relations & Corporate Communications
(604) 558-1784 
[email protected]

Media Contact

Alan Bayless, Longview Communications and Public Affairs
604-417-9645
[email protected]

Pretium Resources Inc.

Suite 2300, Four Bentall Centre, 1055 Dunsmuir Street
PO Box 49334 Vancouver, BC V7X 1L4
(SEDAR filings: Pretium Resources Inc.)

Cautionary Statements Regarding Forward-Looking Statements

This news release contains “forward-looking information” and “forward looking statements” within the meaning of applicable Canadian and United States securities legislation (collectively herein referred to as “forward-looking information”), including the “safe harbour” provisions of Canadian provincial securities legislation and the U.S. Private Securities Litigation Reform Act of 1995, Section 21E of the U.S. Exchange Act and Section 27A of the U.S. Securities Act of 1933, as amended.

Wherever possible, words such as “plans”, “expects”, “guidance”, “projects”, “assumes”, “budget”, “strategy”, “scheduled”, “estimates”, “forecasts”, “anticipates”, “believes”, “intends”, “modeled”, “targets” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative forms of any of these terms and similar expressions, have been used to identify forward-looking information. Forward-looking information contained herein includes but is not limited to: Pretivm ceasing to be a reporting issuer and de-listing from the TSX and the NYSE, and deregistering under the U.S. Exchange Act, following the completion of the Transaction.

Forward-looking information is subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual results, actions, events, conditions, performance or achievements to materially differ from those expressed or implied by the forward-looking information, including, without limitation, that Pretivm may not cease to be a reporting issuer or that its shares may not be de-listed from the TSX or the NYSE on the timeline currently anticipated, and such other risks as are identified in Pretivm’s public disclosure documents filed on SEDAR at www.sedar.com and in the United States through EDGAR at the Security and Exchange Commission’s website at www.sec.gov (collectively, the “Pretivm Disclosure Documents”). This list is not exhaustive of the factors that may affect any of our forward-looking information. Although we have attempted to identify important factors that could cause actual results, actions, events, conditions, performance or achievements to differ materially from those contained in forward-looking information, there may be other factors that cause results, actions, events, conditions, performance or achievements to differ from those anticipated, estimated or intended.

Our forward-looking information is based on the assumptions, beliefs, expectations and opinions of management on the date the statements are made, many of which may be difficult to predict and beyond our control. In connection with the forward-looking information contained in this news release, we have made certain assumptions about, among other things: Pretivm ceasing to be a reporting issuer and having its shares de-listed from the TSX and the NYSE, and the timeline related thereto. Although we believe that the assumptions inherent in forward-looking information are reasonable as of the date of this news release, these assumptions are subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking information. The Company cautions that the foregoing list of assumptions is not exhaustive. Other events or circumstances could cause actual results to differ materially from those estimated or projected and expressed in, or implied by, the forward-looking information contained in this news release.

Additional information about the risks and uncertainties concerning forward-looking information and material factors or assumptions on which such forward-looking information is based is provided in the Pretivm Disclosure Documents. Forward-looking information is not a guarantee of future performance. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Forward-looking information involves statements about the future and is inherently uncertain, and our actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors, including, without limitation, those referred to in this news release and the Pretivm Disclosure Documents. For the reasons set forth above, readers and prospective investors should not place undue reliance on forward-looking information.

We do not assume any obligation to update forward-looking information, whether as a result of new information, future events or otherwise, other than as required by applicable law. Neither the TSX nor the NYSE has approved or disapproved of the information contained herein.

BERKELEY, Calif. and MAINZ, Germany, March 09, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today key strategic and operational results for the year ended December 31, 2021.

Key Highlights and 2021 Accomplishments

• Executed successful U.S. Initial Public Offering (IPO) onto Nasdaq
• Accelerated EU commercialization of ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer
• Bolstered management team with the addition of Karen Richards as Vice President of Regulatory Affairs and Steve Quinn as Vice President of Business Development
• Established Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization
• Participated in leading healthcare industry and investor conferences

Recent Developments

• Acquired portfolio of novel mRNA biomarkers to potentially upgrade ColoAlert’s technical profile to achieve “gold standard” status for CRC at-home testing
• Consummated a $25.8 million public follow-on offering
• Commenced clinical study (ColoFuture) to evaluate potential integration of these biomarkers into ColoAlert
• Initiated communications with the U.S. Food and Drug Administration (FDA) and Centers for Medicare Services (CMS) for ColoAlert clinical trials and reimbursement strategies, including having its pre-submission accepted for review by the FDA

“The past year was an exceptional period of growth for the company highlighted by our transformational milestone of going public onto the Nasdaq stock exchange,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Heading into the second quarter of 2022, I’m extremely pleased with the pace of progress being made on commercial and U.S. regulatory fronts for our flagship product ColoAlert, and we are well positioned to facilitate achieving our goal of becoming the leading developer of cancer-focused molecular diagnostics.”

Commercial Update: ColoAlert being rolled out across Europe via unique business model

In December 2021, Mainz commenced its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. Under the standard terms of all partnerships, Mainz is providing ColoAlert to the respective labs, including co-branding with key accounts, whereby each facility purchases Mainz’s customized polymerase chain reaction (PCR) assay kits on an on-demand basis and provides to their respective network of physicians and patients a comprehensive solution for advanced CRC protection. As a start, the Company announced (December 14^th), a partnership with GANZIMMUN Diagnostics AG (GD), one of Europe’s leading laboratories for preventive and complementary medicine. GD has an interdisciplinary team of over 370 medical technical assistants, physicians, chemists, biologists, and nutritionists who process approximately 5,500 laboratory orders daily. Mainz is now embarking on an aggressive program to ramp up this commercial plan as evidenced by the recent (February 2022) announcement of a partnership with Labor MVZ Dr. Stein + Kollegen (“Laboratory Mönchengladbach”), one of the largest diagnostics laboratories in the North Rhine-Westphalia region of Germany. With a team of over 500 employees that includes biologists, chemists, doctors and other specialists, Laboratory Mönchengladbach services over 2500 physicians, processing over five million samples in total annually and screening approximately 1000 patients per week specifically for CRC.

ColoAlert R&D Update: ColoFuture study evaluating acquired mRNA biomarkers

In February 2022, Mainz initiated a clinical study (ColoFuture) to evaluate a portfolio of five gene expression biomarkers acquired from Socpra Sciences Santé Et Humaines S.E.C. in January 2022. The results from a published study in the peer review journal MDPI (March 11, 2021) demonstrated that these specific biomarkers have a high degree of effectiveness in detecting CRC lesions including advanced adenomas (“AA”), a type of pre-cancerous polyp often attributed to this deadly disease. As such, the ColoFuture study will determine if the biomarkers enhance ColoAlert’s technical profile to extend its capability to include the identification of advanced adenomas (AA) while increasing ColoAlert’s rates of diagnostic sensitivity and specificity. If the data results from ColoFuture are successful, ColoAlert will be positioned as the most robust and accurate at-home diagnostic screening test on the market, as it will not only detect cancerous polyps with a high degree of accuracy, but has the potential to prevent CRC through early detection of precancerous adenomas. The ColoFuture study will enroll over 600 patients in the age range of 40-85 at two participating centers in Norway and two in Germany. The Company expects to complete enrolment during the second half of 2022 and is targeting reporting study results in early 2023. Additionally, data results from ColoFuture will impact ColoAlert’s profile for FDA submission.

ColoAlert’s U.S. Regulatory Approval Update: Pre-submission for pivotal trial design accepted for review by the FDA

In February 2022, Mainz announced that ColoAlert’s pre-submission filed with the U.S. Food & Drug Administration (FDA) for ColoAlert has been accepted for review. The FDA will now provide feedback to the Company on its proposed pivotal U.S. clinical trial design for the test which is expected in Q2 2022. As part of the Company’s activities to prepare for the initiation of the pivotal trial, Mainz established a partnership with Precision for Medicine (November 2021), a leading global Clinical Research Organization (CRO) in which the CRO will work with Mainz’s management team to develop and implement the U.S. focused regulatory and market access strategy for ColoAlert. This will include assistance in drafting ColoAlert’s clinical development plan to ensure the trial design is cost-effective, robust, and efficient. Inherent to this exercise will be the integration of CMS guidelines, utilizing currently marketed CRC screening tests as benchmarks to provide ColoAlert with an optimal product profile for regulatory approval and success in the marketplace.

Corporate Update: Positioned for long-term success

In November 2021, Mainz executed a successful IPO onto Nasdaq raising $11.5 million by placing 2,300,000 common shares at a public offering price of $5.00 per share. And in January 2022, the Company announced a $25.8 million public follow-on offering consisting of 1,725,000 of ordinary shares priced at $15.00 per share. Boustead Securities, LLC acted as the sole underwriter for both transactions. The Company plans to file its Report on Form 20-F, including audited financial statements for 2021, with the U.S. Securities and Exchange Commission in late March or early April.
  
About ColoAlert
ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemistry test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the European Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.
*Dollinger MM et al. (2018)

About Colorectal Cancer

Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late-stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimates that in 2021 there will be approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently, there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US-based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.

About Mainz Biomed N.V.

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with an FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

For more information, please visit www.mainzbiomed.com

For media enquiries, please contact [email protected] 

For investor enquiries, please contact [email protected] 

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021 as well as the Prospectus filed on January 21, 2022. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

WISeKey
’s
WISeID
Platform
H
elps
I
ndividuals and
C
ompanies
R
educe
C
ybersecurity
R
isks

WISeKey
offers
free
access to
cybersecurity services
to
anyone
in
need
of
protect
ing
their digital assets

GENEVA
–
March
9
, 202
2: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, AI, Blockchain and IoT company, today announced that it has enabled free access to its WISeID cyber security platform of services, aiming to reduce the attack-surface on digital assets and personal information, and securely dematerialize electronic transactions.

WISeID, based on the WISeKey/OISTE Root of Trust, integrates innovative technologies to offer any individual or business entity, the ability to create an account, accessing several basic services, free of charge, which then can be upgraded to access additional multiple cybersecurity services. The WISeID web services and Mobile Applications, already available for download and use, provide users with a digital identity that can be used to secure email communication, digitally sign documents with legal validity and is complemented with features such as dual factor authentication and single sign-on.

WISeID now also includes Cloud Storage, a new feature that enables users to keep a protected vault in the Cloud, using servers secured by WISeKey’s Swiss technologies. WISeID Cloud Storage can be used to store confidential documents in a personal Cloud safe area and be shared securely with other WISeID users, so removing risks for eavesdropping and privacy loss. WISeID Cloud Storage facilitates ubiquitous access to users’ personal files through multiple secure interfaces, like web browser, mobile applications for iOS and Android devices and desktop applications for Windows, Mac and Linux. WISeID Cloud is fully compliant with the EU New Data and Cloud Alliance which offers a broader push toward digital sovereignty, and it is intended to reduce dependencies from foreign technology providers.

The WISeID security features are offered as a freemium service, where users can benefit from a free trial service, fully enabled to cover urgent needs and then, given the choice to purchase digital certificates or permanent storage with secure backup and other advantages, through an annual subscription. The service will also be offered to selected companies, in a B2B model. WISeID is accessible as a web service via the WISeId.com trust services portal and enterprise standard APIs that allow the integration with business applications. For more information visit https://wiseid.com.

“Cybersecurity is essential during these complex times. Trusted interactions are based on trust, and trust can only be achieved when all interacting parties can be sure of the identity of their counterpart, and can’t be eavesdropped nor manipulated,” said Carlos Moreira, Founder and CEO of WISeKey.

About WISeKey

WISeKey (NASDAQ: WKEY; SIX Swiss Exchange: WIHN) is a leading global cybersecurity company currently deploying large scale digital identity ecosystems for people and objects using Blockchain, AI and IoT respecting the Human as the Fulcrum of the Internet. WISeKey microprocessors secure the pervasive computing shaping today’s Internet of Everything. WISeKey IoT has an install base of over 1.5 billion microchips in virtually all IoT sectors (connected cars, smart cities, drones, agricultural sensors, anti-counterfeiting, smart lighting, servers, computers, mobile phones, crypto tokens etc.).  WISeKey is uniquely positioned to be at the edge of IoT as our semiconductors produce a huge amount of Big Data that, when analyzed with Artificial Intelligence (AI), can help industrial applications to predict the failure of their equipment before it happens.

Our technology is Trusted by the OISTE/WISeKey’s Swiss based cryptographic Root of Trust (“RoT”) provides secure authentication and identification, in both physical and virtual environments, for the Internet of Things, Blockchain and Artificial Intelligence. The WISeKey RoT serves as a common trust anchor to ensure the integrity of online transactions among objects and between objects and people. For more information, visit www.wisekey.com.

Press and investor contacts:

WISeKey International Holding Ltd

Company Contact:  Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
[email protected]        

WISeKey Investor Relations (US)
Contact:  Lena Cati
The Equity Group Inc.
Tel: +1 212 836-9611
[email protected]

Disclaimer:

This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties, and other factors, which could cause the actual results, financial condition, performance, or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.